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Dietary and nutritional supplements are modulators of HDL cholesterol (HDLc) levels and 
production of apolipoprotein AI (apo AI). Previously, in vitro treatment of hepatocyte cell lines 
with glucosamine increased apo AI production by stabilization of apo AI mRNA. The hypothesis 
is that the neutraceutical, glucosamine, when given in conventional doses (1500g per day) may 
increase apolipoprotein AI and HDLc levels in subjects with diabetes and low HDLc. 
 
Research Design and Methods 
Twelve subjects (3 men /9 women) with type 1(n=2) and type 2 diabetes (n=10), age 55 ± 12 
years (mean ± SD) who had low HDL cholesterol 1.03 ± 0.20 mmol/L were randomized to a 
double-blind placebo-controlled cross-over trial of glucosamine 500 mg or placebo orally three 




Fasting serum glucose, fructosamine and total cholesterol remained stable during the drug and 
placebo phases. Glucosamine had no significant effect post therapy on serum levels of HDLc 
(from baseline of 1.02 ± 0.15 mmol/L to 1.05 ± 0.16 mmol/L compared with placebo from 1.04 
± 0.21 mmol/L to 1.06 ± 0.16 mmol/L), nor in changes in apolipoprotein AI levels (from 
baseline of 147 ±15 mg/dL to 140± 126 mg/dL with glucosamine and 146 ± 25 mg/dL to 142 
±17 mg/dL with placebo).    
 
 Conclusion: 
These observations suggest that glucosamine at commonly consumed doses does not have 
significant effects on glycemic control, lipid profile or levels of apolipoprotein AI in diabetic 
subjects after 2 weeks of supplementation.  
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Introduction 
It is generally accepted that the 
mechanism of the increased risk of 
cardiovascular disease in diabetes is 
multifactorial (1). One such factor is probably 
the reduced serum levels of high-density 
lipoprotein cholesterol (HDLc) in obese type 
2 diabetic people (1, 2).  Dietary composition 
and nutritional supplements are important 
modulators of HDLc level and the production 
of its main apolipoprotein namely 
apolipoprotein AI (apo AI) (3). Glucosamine, 
a popular nutritional supplement for treating 
arthritis, has been shown to alter apo AI 
production in hepatocyte cultures (4).  
  Endogenous glucosamine is synthesized 
by the amidation
 of glucose-6-phosphate via 
the hexosamine biosynthetic pathway
 (HBP) 
(5). Approximately 5% of glucose-6-
phosphate is metabolized
  to  N-
acetylglucosamine (GlcNAc) by glutamine: 
fructose-6-phosphate
  amidotransferase.  In 
addition, the extracellular glucosamine is 
transported into
  tissues and is subsequently 
phosphorylated to enter the HBP. This 
pathway has been implicated in insulin 
resistance that may contribute
 to diabetes and 
cardiovascular diseases (5). 
Commercially available products 
containing glucosamine are used extensively 
as neutraceuticals in the treatment of arthritis, 
and have been shown in large clinical trials to 
be safe in conventional doses (1500g per day) 
(6, 7).  Parenteral administration of high doses 
of glucosamine (i.e., 5-30 µmol/kg/min) may 
cause diabetes in experimental animals (8). 
Studies in healthy human controls who 
received a peripheral infusion of low dose 
glucosamine (1.6 µmol/ kg/ min, steady state 
plasma levels of 0.57 mmol/L) showed no 
change in parameters of glucose homeostasis.  
High dose continuous infusion of 
glucosamine (5 µmol/ kg/ min, steady state 
plasma levels of 1.15 mmol/L) was associated 
with minimal abnormalities in insulin 
secretion, glucose tolerance or insulin 
mediated glucose metabolism (8). 
Furthermore, clinical trials in subjects with 
type 2 diabetes subjects have found that 
glycemic control does not deteriorate 
following treatment with 1500 mg 
glucosamine /1200 mg chondroitin per day 
over 90 days duration (9). 
We have previously reported that 
treatment of hepatocyte cell lines in culture 
with glucosamine increases apo AI production 
as a result of stabilization of apo AI mRNA 
(4). It is not known if this observation is 
clinically relevant and whether glucosamine 
supplementation in diabetic subjects, who 
tend to have low apo AI levels, would 
ameliorate the hypoalphalipoproteinemic 
state. Improvements in apo AI and HDLc by 
glucosamine would potentially reduce the 
cardiovascular risk in diabetes.  Therefore the 
present study was carried out to test the 
hypothesis that glucosamine supplementation, 
when given in currently acceptable doses, 
may increase apolipoprotein AI and HDLc 




       Subjects  Subjects with either type 1 or 
type 2 diabetes mellitus were recruited from 
the endocrinology clinics of Saint Louis 
University. Inclusion criteria allowed patients 
with HDL cholesterol ≤ 1.29 mmol/L and at 
least 1 of the following: triglycerides ≥ 2.30 
mmol/L, abdominal obesity (waist 
circumference > 102 cm in men or > 88 cm in 
women) or hypertension (BP > 130/85 mmHg 
before treatment). They were randomized to a 
double-blind placebo-controlled cross-over 
trial of glucosamine 500 mg orally three times 
a day or matching placebo for 2 weeks, 
followed by a  4 week wash-out phase, and 
then a 2 week cross-over to the alternate 
therapy of placebo or glucosamine.  
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        All  had  stable  glycohemoglobin  and 
were not allowed to have any new class of 
antiglycemic medications within the previous 
2 months of enrollment. Subjects who were 
already on lipid modifying agents for at least 
the past 2 months such as - statins, fibrates, 
niacin, ezetimibe, binding resins, glitazones, 
fish oil, estrogen, or selective estrogen 
receptor modulators, continued without 
change in the dose of medication.  
        Subjects were excluded if they had any 
recent myocardial infarction or 
revascularization procedure (within 6 weeks), 
renal disease ( serum creatinine >177 
µmol/L), recent surgery ( within 6 weeks), 
weight loss of  > 5% of body weight within 
the preceding 3 months, liver disease 
(abnormal liver enzymes or liver function 
tests), chronic hepatitis, or were pregnant.   
        All  subjects signed a consent form 
approved by the Institutional Review Board 
of Saint Louis University. They were 
randomized by computer generated random 
number allocation to initial treatment with 
glucosamine or matching placebo. 
Independent analysis of random pills were 
determined to be >99.5% pure by chemical 
analysis of glucosamine content by HPLC 
(10).  
        Laboratory  measurements  were 
determined in the clinical laboratories of 
Quest Diagnostics, St. Louis MO, using 
standard laboratory ranges of glucose, 
cholesterol, HDLc, low density lipoprotein   
cholesterol (LDLc), Triglycerides, 
glycohemoglobin, fructosamine (reference 
range 190-270 µmol/L) , apo AI, (reference 
range for males: 94-176 mg/dL, for females: 
101-198 mg/dL) and apolipoprotein B, apo B, 
( reference range for males: 52-109 mg/dL, 
for females: 49-103mg/dL). 
       Statistical  analysis: Changes in lipid 
levels and lipoprotein levels were analyzed by 
paired parametric testing by analysis of 
variance of repeated measures. The efficacy 
of glucosamine in increasing hepatic apo AI 
production in cell culture studies was used to 
calculate the number of subjects needed to 
demonstrate a clinical effect. In these cell 
culture studies, glucosamine treatment of cells 
at the lowest dose tested (0.03 mmol/L) was 
associated with 80% increase in apo AI levels 
in the culture media (4). It was estimated that 
to demonstrate a 10% improvement in 
apolipoprotein AI levels with glucosamine 
treatment, twelve subjects would have a 
power of >80 % for an α =0.05 by 2-tailed 
paired testing.  
     Statistical procedures were performed with 
the statistical package Statistica for Windows 
(version 7, Statsoft, Inc, Tulsa, OK). 
Significance was defined as P<0.05 by two-
tailed testing.  
 
Results and Discussion:  
       Twelve  subjects  with  type  1  (n=2)  and 
type 2 diabetes (n=10) were enrolled.  The 
demographics of the study population are 
summarized in Table 1. Table 2 summarizes 
the glycemic and lipid profile of the subjects 
throughout the study. Treatment with 
glucosamine, 500mg three times a day for two 
weeks did not alter the glycemic control 
parameters such as fasting glucose or 
fructosamine level, and did not alter the 
serum lipid and lipoprotein levels.  
       The lack of significant effect on glycemic 
parameters is consistent with previously 
published studies on the effect of glucosamine 
in both diabetic and non-diabetic people (9, 
11). Of particular interest in this study was the 
lack of a change in HDLc or apo AI levels 
following glucosamine treatment for 2 weeks. 
This outcome was contrary to our 
expectations based on our previous studies 
showing a significant effect of glucosamine 
on apo AI production in hepatocytes (4).  
          Several potential variables may explain 
the discrepancy between the in vivo effects of 
glucosamine and the effects observed in cell 
cultures. Interference of glucosamine with the 
assays reported is unlikely and has not been 
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previously observed (8, 9, 11). Apo AI’s half 
life has been estimated to be 15-54 hours (12). 
In people with diabetes and 
hypertriglyceridemia the fractional catabolic 
rate of HDL and apo AI is increased (13). 
Thus, given the known kinetics of apo AI and 
HDLc, two-week’s treatment is sufficient to 
demonstrate a meaningful effect on steady 
state levels of HDLc and apo AI. 
          The dose of glucosamine however may 
have been insufficient to effect a change. The 
choice of the dose was based on what is 
commonly prescribed and based on 
precautionary considerations that higher doses 
of glucosamine may have adverse metabolic 
effects (11). A single oral dose of 500 mg 
glucosamine results in a peak concentration of 
2 to 5 µmol/L and is eliminated with a mean 
apparent plasma elimination half-life of 148 
min (11). Given such elimination kinetics, the 
plasma glucosamine levels would not reach a 
steady state when glucosamine supplements 
are taken on a three times a day schedule.  
If the peak concentrations achievable after a 
500 mg dose of oral glucosamine is 5 µmol/L, 
and assuming that hepatic first pass accounts 
for 25% bioavailability of glucosamine (11) it 
can be assumed that the liver is exposed to 
concentrations of glucosamine in the range of  
20 µmol/L  This is somewhat lower than the 
lowest concentration of glucosamine (30 
µmol/L ) used in cell culture studies (4). Thus 
the dwell time in plasma may be short and the 
concentration not high enough for the 
intended effect.  It is possible that higher or 
more frequent dosing may have an effect on 
the apo AI metabolism, but there is 
insufficient safety data available for these 
dose adjustments.  
       Another  potential  confounding  factor  is 
the variability of the active ingredient content 
of glucosamine pills (10). Therefore we 
measured the active ingredient in a random 
samples of the pills used in the study to 
document the reliability of the commercial 
product.  
          The sample size may have limited the 
capacity of this study to detect a significant 
effect of glucosamine on apo AI levels. The 
magnitude of the increase in apo AI 
production following glucosamine treatment 
of hepatocytes in cultures was highly 
significant (4). Glucosamine was used at 
doses of 0.03, 0.1, 0.3, 1.0 and 3.0 mmol/L. 
The changes in apo A1 was significant even 
at 0.03 mmol/L (763 arbitrary integrator units 
[AIU] vs. baseline values of 423 [AIU]) and 
at 1.0 mmol/L there was 5.5 fold increase in 
apo A1 protein and 2.4 fold increase in apo 
A1 mRNA.  The current study was designed 
to document a 10% change in apo AI. Twelve 
subjects would have been sufficient to 
provide a power of >80% at an α =0.05 to 
demonstrate a 10% improvement in 
apolipoprotein AI levels with glucosamine 
treatment by 2-tailed testing. It is possible that 
given the limited number of the subjects 
studied a more modest increase in apo AI 
levels may have been missed.  
         It  is  also possible that given the 
multiplicity of factors that suppress apo AI 
production in diabetes (2), the effect of 
glucosamine will not be demonstrable in this 
population. It is noteworthy that a recent 
study in non-diabetic lean or obese  subjects 
could not show a significant change in HDLc 
levels following 6 weeks of treatment with 
1500 mg glucosamine daily (11).  
        A  recently  published  randomized 
placebo-controlled study examined whether 
glucosamine has an antirheumatic effect in 51 
rheumatoid arthritis patients (14). 
Glucosamine hydrochloride at a daily dose of 
1,500 mg and placebo were administered for 
12 weeks along with conventional 
medication. While significant improvement 
was not found in objective measures of 
severity of disease, pain was significantly 
reduced in the glucosamine group. Since 
glucosamine has been used in the treatment of 
osteoarthritis (6, 7) and rheumatoid arthritis 
(14), it would therefore be useful to know the 
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effect of this treatment on plasma lipid 
profile. The mechanism of action of 
glucosamine in its antiarthritic effect is 
largely unknown, but seems to involve an 
anti-inflammatory effect (15). This implies an 
effect on circulating inflammation mediators 
some of which, notably TNF α and IL-1β are 
known to down-regulate apo AI production 
and reduce HDLc levels (16, 17). Thus it is 
possible that the potential salutary effects of 
glucosamine on HDLc may be more 
pronounced in those individuals in a chronic 
inflammatory state such as arthritis, compared 
to nonarthritic patients with diabetes where 
the degree of chronic inflammation may be 
less.  
        Overall  these  observations  suggest  that 
glucosamine at doses commonly consumed by 
the public does not have significant effect on 
glycemic control or lipid profiles of subjects 
with diabetes after 2 weeks of 
supplementation. The effects of glucosamine 
previously shown in hepatocyte cultures are 
not demonstrable clinically in subjects with 
diabetes when glucosamine is consumed at 
commonly used amounts.  
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Table 1: The demographics and baseline laboratory findings of study participants at screening visit  
PARAMETERS  Mean (SD) 
Sex, M/F  3 / 9 
Diabetes type,  1/ 2  2 / 10 
Age, years  55(12) 
Height, m  1.75(0.14) 
Weight, Kg  114.9(42.5) 
BMI, kg/m
2 36.7 (9.9) 
Hypolipemic drugs (doses)   
Atorvastatin (10mg/20mg/80 mg)  N= 1/1/1 
Lovastatin (20mg/40 mg)                                         N= 1/1 
Pravastatin ( 40mg)                                         N=2 
Nicotinic acid (2000mg)                                         N=1 
Ezetimibe (10mg)                                         N=1 
Ezetimibe (10mg) + Rosuvastatin (10mg)                                         N=1 
None                                          N=2 
Glycohemoglobin, %  7.9 (1.4) 
Fructosamine µmol/L  289(71) 
Fasting glucose, mmol  9.12 (4.04) 
Cholesterol, total, mmol/L   4.16 (0.75) 
Cholesterol, HDL, mmol  1.03 (0.20) 
Cholesterol, LDL, mmol/L  2.24 (0.68) 
Triglycerides, mmol  2.65 (1.44) 
Apoprotein A1, mg/dL  146(19) 
Apoprotein B, mg/dL  95 (18) 
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Table 2. The mean +/- SD of serum concentrations of glucose, fructosamine as well as lipid and 
lipoproteins prior to (Pre) and following two weeks of (Post) treatment with glucosamine (500 mg) or 
placebo orally three times a day.   
 Pre  Post  Pre  Post 
Parameter Glucosamine 
Mean ( SD) 
Glucosamine  
Mean (SD) 




Glucose, mmol/L  9.5 (5.4)  10.3 (4.9)  9.5 (4.2)  10.5 (6.2) 
Cholesterol, mmol/L  4.16 (0.63)  4.14 (0.77)  4.20 (0.76)  4.19 (0.84) 
HDLc, mmol/L  1.02 (0.15)  1.05 (0.16)  1.04 (0.21)  1.06 (0.16) 
LDLc, mmol/L  2.19 (0.59)  2.26 (0.58)  2.20 (0.65)  2.12 (0.63) 
Triglycerides, mmol/L  2.81 (1.49)  2.64 (1.97)  2.86 (1.61)  3.02 (2.01) 
Fructosamine, µmol/L  309 (104)  330 (139)  298 (74)  327 (97) 
Apoprotein A1,mg/dL  147 (15)  140 (16)  146 (25)  142 (17) 
Apo[protein B, mg/dL  91 (22)  89 (17)  91 (16)  95 (27) 
 
 
 